503A vs. 503B compounding: what prescribers should know

Start with the patient and the intended supply

A prescription for an identified patient and an order for a clinic’s office supply are different requests. Before selecting a compounder, make clear who will receive the medication, where it will be dispensed or administered, and whether the order identifies an individual patient. That conversation gives the pharmacist a useful starting point for reviewing the request.

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act establish different conditions for human drug compounding. They describe regulatory frameworks, rather than a ranking of pharmacies. A clinic still needs to evaluate the specific facility, preparation and patient need.

503A centers on an identified patient

Section 503A addresses compounding by licensed pharmacists in state-licensed pharmacies or federal facilities, and by licensed physicians. One condition is a valid prescription for an identified individual patient. Limited anticipatory compounding is possible under specified conditions; it does not remove the patient-specific prescription requirement for distribution.

When all applicable conditions are met, section 503A provides exemptions from certain federal requirements, including current good manufacturing practice requirements. This does not mean that no quality standards or oversight apply. State boards generally provide day-to-day oversight of these pharmacies, and FDA also has authority over compounded drugs.

• FDA comparison of applicable compounding provisions

503B establishes outsourcing facilities

An outsourcing facility elects to register with FDA under section 503B and must meet that section’s conditions. These facilities compound sterile drugs by or under a licensed pharmacist’s direct supervision. The federal framework allows distribution for office stock without a prescription for each identified patient when applicable conditions are met. State requirements must also be checked; FDA registration alone does not establish permission for every clinic order or destination.

Outsourcing facilities remain subject to current good manufacturing practice requirements. FDA inspects them on a risk-based schedule, and they have reporting obligations, including adverse-event reporting. Registration identifies a regulatory category; it does not make a facility’s compounded drugs FDA-approved.

• FDA information for outsourcing facilities

Questions to bring to the pharmacy

Use the distinction to make the ordering conversation more precise. A useful initial discussion can cover:

• Which facility will compound the preparation, and which entity will dispense it?
• Is this request for an identified patient or for office supply?
• What licenses or registrations apply to the facility and the destination?
• Which formulation, labeling, storage and delivery questions need resolution before an order is accepted?
• Who should the clinic contact about a product concern or a change to the prescription?

Keep FDA approval separate from registration

FDA does not approve compounded drugs or review them for safety, effectiveness and quality before marketing. FDA advises using compounded drugs only when an available FDA-approved drug cannot meet a patient’s medical needs. The prescriber and pharmacist should address that need alongside the ordering pathway.

This article is general educational information, not medical or legal advice. Consult the pharmacist and applicable authorities about a specific prescription or office-supply arrangement.